Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in Glycogen Storage Disease Type I
NCT03665636Phase 1Completed
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cenegermin in glycogen storage disease type I. Primary endpoint: Blood glucose level at 6 months. Started Oct 2020; status: completed.
02
Drugs
cenegermin
03
Conditions
glycogen storage disease type I
Beyond the preview
Go deeper on NCT03665636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665636.